循环肿瘤DNA检测西妥昔单抗联合化疗一线治疗晚期结直肠癌的获得性基因突变

Circulating Tumor DNA for Acquired Genomic Alterations on First⁃Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer

下载PDF

导出

摘要 1文献来源Raghav K,Ou F-S,Venook AP,et al. Acquiredgenomic alterations on first-line chemotherapy with cetuximab in advanced colorectal cancer:circulatingtumor DNA analysis of the CALGB/SWOG-80405Trial (Alliance)[J]. J Clin Oncol, 2022:JCO2200365. Online ahead of print.2证据水平1b。

作者廖旺军徐飞 LIAO Wang-jun;XU Fei(Department of Oncology,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China;不详)

机构地区南方医科大学南方医院肿瘤内科肿瘤内科

出处《循证医学》 2022年第5期268-271,共4页 The Journal of Evidence-Based Medicine

关键词西妥昔单抗晚期结直肠癌获得性突变 cetuximab advanced colorectal cancer acquired genomic alterations

分类号 R735.3 [医药卫生—肿瘤]

引文网络
相关文献

参考文献2

1Guillermo Valenzuela,Mauricio Burotto,Katherine Marcelain,Jaime Gonzalez-Montero.Liquid biopsy to detect resistance mutations against anti-epidermal growth factor receptor therapy in metastatic colorectal cancer[J].World Journal of Gastrointestinal Oncology,2022,14(9):1654-1664. 被引量：1
2Na Huang,Dongqiang Zeng,Xiaoxiang Rong,Chunlin Wang,Zhenzhen Wu,Jian Guo,Yuqi Wang,Jin Li,Jing Li,Jiao Wang,Siting Zheng,Genjie Huang,Jianping Bin,Yulin Liao,Qian Li,Xin Yi,Wangjun Liao,Min Shi.Evolution of tumor microenvironment in colorectal liver metastases under treatment stress[J].Cancer Communications,2022,42(5):471-475. 被引量：1

二级参考文献3

1Kyle Knickelbein,Lin Zhang.Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer[J].Genes & Diseases,2015,2(1):4-12. 被引量：15
2Guillermo Valenzuela,Joaquín Canepa,Carolina Simonetti,Loreto Solo de Zaldívar,Katherine Marcelain,Jaime González-Montero.Consensus molecular subtypes of colorectal cancer in clinical practice:A translational approach[J].World Journal of Clinical Oncology,2021,12(11):1000-1008. 被引量：1
3Vincenzo Sforza,Erika Martinelli,Fortunato Ciardiello,Valentina Gambardella,Stefania Napolitano,Giulia Martini,Carminia della Corte,Claudia Cardone,Marianna L Ferrara,Alfonso Reginelli,Giuseppina Liguori,Giulio Belli,Teresa Troiani.Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer[J].World Journal of Gastroenterology,2016,22(28):6345-6361. 被引量：8

1武强,孔浩,张博友,钱邦伦,卢毅,孙飞,史宏灿.早期非小细胞肺癌外科手术方式的争议[J].中国胸心血管外科临床杂志,2022,29(8):1066-1072. 被引量：9
2邱萌,MEYERHARDT J A,SHI Q,FUCHS C S.标准辅助化疗基础上增加塞来昔布或安慰剂对Ⅲ期结肠癌患者无复发生存的疗效对比研究:CALGB/SWOG 80702(Alliance)随机对照研究[J].结直肠肛门外科,2021,27(3):267-268. 被引量：6
3Mei-Hong Liu,Yan-Xia Li,Zhuo Liu.Envafolimab combined with chemotherapy in the treatment of combined small cell lung cancer: A case report[J].World Journal of Clinical Cases,2023,11(5):1115-1121. 被引量：1
4林淑君,蓝佳琦,沈惠群,郭孟贤.伊立替康联合西妥昔单抗治疗老年晚期结直肠癌临床研究[J].中国医药科学,2023,13(8):150-153. 被引量：3
5张荣欣,陈功,ANDRÉ T,MEYERHARDT J,IVESON T.Ⅲ期结肠癌患者辅助化疗持续时间的影响研究(IDEA研究合作组):基于6项Ⅲ期随机试验数据的前瞻性汇集分析最终结果[J].结直肠肛门外科,2021,27(1):75-77. 被引量：12
6陈豪,潘晓飞,张好刚,王夫景,乔鹏飞.结直肠癌患者肿瘤类器官生物样本库在预测化疗效果中的应用研究[J].中国普外基础与临床杂志,2023,30(2):167-174. 被引量：3
7曹玓,陈功,徐飞.MRD:希望与挑战共存——评ctDNA在Ⅱ期结肠癌辅助化疗决策中的价值[J].循证医学,2022,22(5):272-276. 被引量：1
8Hi-Ju Hong,Yanfei Shao,Sen Zhang,Guang Yang,Hongtao Jia,Xiao Yang,Ling Huang,Shuchun Li,Batuer Aikemu,Luyang Zhang,Junjun Ma,Lu Zang,Jing Sun,Minhua Zheng.ACACB is a novel metabolism-related biomarker in the prediction of response to cetuximab therapy in metastatic colorectal cancer[J].Acta Biochimica et Biophysica Sinica,2022,54(11):1671-1683. 被引量：1
9Rui Xu,Hui Peng,Ning Yang,Zhenping Liu,Wei Lu.Nuclear lncRNA CERNA1 enhances the cisplatin-induced cell apoptosis and overcomes chemoresistance via epigenetic activation of BCL2L10 in ovarian cancer[J].Genes & Diseases,2023,10(1):10-13.
10罗世书,屈杰,周楠,徐翠香,刘屹,张丽洁,王建华.289例单克隆抗体抗肿瘤药品不良反应报告分析[J].中国药物警戒,2023,20(4):444-448. 被引量：3

循证医学

2022年第5期

浏览历史

内容加载中请稍等...

循环肿瘤DNA检测西妥昔单抗联合化疗一线治疗晚期结直肠癌的获得性基因突变

参考文献2

二级参考文献3

相关作者

相关机构

相关主题

浏览历史